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PspA is one of the most well studied pneumococcal proteins and a promising candidate for a future
protein-based anti-pneumococcal vaccine. Nevertheless, its structural and serological variability sug-
gests the inclusion of more than one PspA molecule in order to broaden protection. Since different PspAs
exhibit variable levels of cross-reactivity, the selection of the protein combination with the highest cov-
erage potential is an essential step for PspA-based vaccine development. This work investigated the
level of cross-reactivity within family 1 PspAs, and established a complement based antibody medi-
ated opsonophagocytic assay for measuring the level of cross-protection. Among a panel of ten family
1 PspA molecules, two of them, one belonging to clade 1 and another from clade 2, induced antibodiestreptococcus pneumoniae
omplement
spA
psonophagocytosis
capable of enhancing complement deposition and mediating the phagocytic killing by mouse peritoneal
macrophages of all pneumococci bearing PspA family 1 strains tested, regardless of their serotype. There-
fore, we suggest the inclusion of either one in a PspA-based vaccine, as a representative of family 1.
Furthermore, our results suggest that opsonophagocytosis by mouse peritoneal cells can be an efﬁcient
means of evaluating the induction of protective immune responses in mice across a large number of
strains.
. Introduction
Streptococcus pneumoniae is a major cause of diseases such
s meningitis, bacteremia, sinusitis, acute otitis media and pneu-
onia [1]. Pneumococcal diseases are responsible for millions of
eaths every year, especially in developing countries [2]. The cur-
ent pneumococcal vaccines are basedon capsular polysaccharides.
he 23-valent polysaccharide vaccine is poorly immunogenic in
nfants, offering clinical protection rates of about 60% in adults
3]. The 7-valent conjugate vaccine elicits protection in young chil-
ren, but only against the seven included serotypes [4–7]. Recently,
0-valent and 13-valent vaccines have been licensed [8,9], but
he potential replacement by non-vaccine serotypes and the high
∗ Corresponding author. Tel.: +55 11 2454 8076.
E-mail addresses: michelle.bertoncini@saofrancisco.edu.br,
ampaiomichelle@uol.com.br (M. Darrieux).
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cost reinforce the need for cost-effective strategies, such as a
protein-based pneumococcal vaccine. Several proteins have been
investigated as vaccine candidates against pneumococcus, includ-
ing the Pneumococcal surface proteinA (PspA). This is an important
virulence factor, expressed on the surface of all pneumococcal
strains [10], able to inhibit complement activation by the classic
and alternative pathways [11]. PspA displays variability at the level
of DNA sequence, although there are many sequence similarities
and serologically cross-reactive epitopes [12]. The N-terminus of
PspA contains the majority of protection-eliciting epitopes [13],
and has been divided into three regions, A, B and C [12]. Based on
the sequence variations within the B region, PspA has been classi-
ﬁed into family 1 (clades 1 and 2), family 2 (clades 3, 4 and 5) and
Open access under the Elsevier OA license.family 3 (clade 6) [12]. Families 1 and 2 are the most prevalent,
being present in more than 90% of clinical isolates [14–17].
PspA is highly immunogenic and protective in different animal
models [18]. Moreover, antibodies generated by human immu-
nization with a single recombinant PspA showed cross-reactivity
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gainst PspAs from both families [19], as well as passive protec-
ion in mice challenged with S. pneumoniae strains bearing diverse
spAs [20].
Several studies have investigated the level of cross-reactivity
mong PspAs, in mice. The results suggested that the level of cross-
eactivity is proportional to the degree of similarity among the
minoacid sequences, with a tendency for a higher cross-reactivity
ithin the same family [19]. Recent data indicate a considerable
ariation in the ability of antibodies induced against different
ecombinant PspAs to recognize pneumococcal isolates bearing
istinct PspAs. While two family 2 fragments were found to be
ighly cross-reactive, the extension of cross-recognition among
amily 1 molecules was extremely limited; the anti-PspA1 anti-
erum was able to recognize all clade 1-bearing strains and half
f the clade 2-containing strains tested, and the anti-PspA 2 anti-
erum recognized only half of the clade 2-bearing strains and two
f the clade 1-expressing isolates tested [21]. The sequence analy-
is of pspA 2 has shown that the fragment used was more divergent
romother clade2pspAgenes sequencedbyHollingsheadet al. [12].
heseﬁndingswere corroboratedby the limitedability of suchanti-
odies to mediate complement deposition onto the bacterium, an
mportant mechanism of pneumococcal clearance [22]. Altogether,
hese results suggest theneed for selectionof amore representative
amily 1 PspA.
The opsonophagocytic assay (OPA) has beenused as a functional
orrelate of protection for antibodies generated against pneumo-
occal capsular polysaccharide. A minimum opsonic titer of 1:8
s able to confer protection in a mouse model, which correlates
ith protection in infants immunized with pneumococcal conju-
atevaccine, corresponding toan immunoglobulinG (IgG)antibody
oncentration of 0.20–0.35g/ml [23]. However, to date, the OPA
as not been well established for antibodies generated against the
neumococcal surface proteins.
Given that PspAs from the same clade can showvariable degrees
f cross-reactivity, the aim of this study was to determine, from a
anel of Brazilian pneumococcal isolates, which is able to induce
he highest level of cross-reactivitywithin family 1 by immunoblot,
omplement deposition and an opsonophagocytic assay using
ouse peritoneal cells.
. Materials and methods
.1. Construction of PspA fragments
All cloningprocedureswereperformedwithEscherichia coliDH5
grown in Luria-Bertani medium supplemented with ampicillin
100g/ml). DNA fragments encoding portions of the N-terminal
egions of PspA clades 1 and 2 were ampliﬁed by PCR from the
enomicDNAof10pneumococcal strains (5of eachclade). Thegene
roductswere ligated to thepGEMT-easyvector (Promega), and the
equences were conﬁrmed by DNA sequencing. The pGEMTeasy-
spA constructs were digested with the appropriate restriction
ndonucleases and the resulting fragments were ligated to the lin-
arized pAE-6xHis vector [24].
.2. PspA expression and puriﬁcation
Competent E. coli BL21(DE3) (Invitrogen) were transformed
ith the pAE-6xHis vectors containing the pspA gene fragments.
rotein expression was induced in the mid-log-phase cultures
y 1mM IPTG (Sigma). The recombinant proteins, bearing an
-terminal histidine tag, were puriﬁed from the soluble frac-
ion through afﬁnity chromatography with Ni2+ charged chelating
epharose resin (HisTrap Chelating HP; GE HealthCare) in an Akta
rime apparatus (GE HealthCare). Elution was carried out with9 (2011) 1634–1642 1635
500mM imidazole. The puriﬁed fractionswere analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
dialyzed against 10mM Tris–HCl (pH 8) – 20mM NaCl, and stored
at −20 ◦C.
2.3. Pneumococcal strains
All strains used in this study are described in Table 1. Pneumo-
cocci were maintained as frozen stocks (−80 ◦C) in Todd-Hewitt
broth supplemented with 0.5% yeast extract (THY) with 10% glyc-
erol. In each experiment, the isolates were plated on blood agar
prior to growth in THY.
2.4. Animals and immunization
Female BALB/c mice from Instituto Butantan (São Paulo, Brazil)
were immunized intraperitoneally with 5g of recombinant PspA
derivatives in saline solution 0.9% with 50g of Al(OH)3 as adju-
vant (500l per mouse). The adjuvant alone was used as a control.
The animals were given three doses of protein at 7-day intervals.
Sera were collected from mice at 14 and 21 days by retro-orbital
bleeding. The antibody titers were examined by ELISA [21].
2.5. Analysis of serum cross-reactivity
Cross-reactivity of anti-PspA antibodies was analyzed by
immunoblot. S. pneumoniae strains were grown in 50ml of THY
to mid- to late-log phase. Bacteria were harvested by centrifu-
gation and the pellets were washed 3× in phosphate-buffered
saline (PBS), suspended in 1ml of 2% choline chloride (Sigma)
in PBS (pH 7.0), incubated for 10min at room temperature and
centrifuged to recover the eluates [25]. Choline extracts (2g)
from pneumococcal strains bearing PspAs of clades 1 and 2
were separated by SDS-PAGE and transferred to nitrocellulose
membranes (GE Healthcare). Pooled anti-PspA sera (six mice per
group) generated against the recombinant PspA fragments of
clades 1 and 2 were added at a dilution of 1:1000 (sera col-
lected after the second immunization), followedby incubationwith
horseradish peroxidase-conjugated goat anti-mouse IgG (diluted
1:1000; Sigma). Detection was performed with an ECL kit (GE
Healthcare).
2.6. Complement deposition assay
S. pneumoniae strains (Table 1) were grown in THY to a con-
centration of 108 CFU/ml (optical density of 0.4–0.5) and harvested
by centrifugation at 2000× g for 3min. The pellets were washed
once with PBS, resuspended in the same buffer, and incubated in
the presence of heat-inactivated pooled sera frommice immunized
with PspA fragments at a ﬁnal concentration of 5% for 30min at
37 ◦C. The sera were heat-inactivated by incubation at 56 ◦C for
30min to destroy the activity of serum complement. Bacteria were
thenwashedoncewithPBS, resuspended in90l of gelatinVeronal
buffer (Sigma), and incubated in the presence of 10% fresh-frozen
normal mouse serum (from BALB/c mice) at 37 ◦C for 30min. After
another wash with PBS, the samples were incubated with 100l
of FITC-conjugated goat antiserum to mouse complement C3 (MP
Biomedicals) at a dilution of 1:500 on ice for 30min in the dark.
Finally, the bacteria were washed two more times with PBS, resus-
pended in 1% formaldehyde, and stored at 4 ◦C in the dark until
analysis with a FACSCanto (BD Biosciences).2.7. Opsonophagocytic assay
S. pneumoniae strains (Table 1) were grown in THY to a con-
centration of 108 CFU/ml (optical density of 0.4–0.5) and harvested
1636 C. Goulart et al. / Vaccine 29 (2011) 1634–1642
Table 1
Pneumococcal strains used in this study.
Strain PspA clade Serotype Source Assay Primers
M12 1 6B UFG Clon; IB a; c
P13 1 9V UFG Clon; IB a; c
P69 1 10A UFG Comp;OPA –
P125 1 15B UFG Comp –
P231 1 6A UFG IB –
245/00 1 14 IAL Clon; IB; Comp;OPA a; d
P630 1 14 UFG Comp –
P1031 1 23F UFG Clon; IB a; c
P1079 1 1 UFG Clon; IB; OPA a; c
3JY44182-95 1 3 UAB OPA –
M8 2 6B UFG IB –
P94 2 19F UFG OPA –
94/01 2 18A IAL Clon; IB; Comp a; d
P278 2 18C UFG Clon; IB; OPA b; d
325/95 2 6A IAL Clon; IB b; d
P339 2 6A UFG Clon; IB b; d
373/00 2 6B IAL Clon; IB; OPA b; d
P854 2 19F UFG Comp; OPA –
A66.1 2 3 UAB IB; Comp –
D39 2 2 UAB IB; Comp –
IAL: Instituto Adolfo Lutz, São Paulo, Brazil.
UFG: Universidade Federal de Goiás, Goiânia, Brazil.
UAB: University of Alabama at Birmingham, USA.
Clon: Cloning of pspA gene fragments.
IB: Immunoblot.
Comp: Complement deposition.
OPA: Opsonophagocytic assay.
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: Forward 5′-ACCATGGTAAGAGCAGAAGAAGCC-3′ .
: Reverse 5′-TTATTCTGGTTTAGGAGCTGGAGCTGG-3′ .
: Reverse 5′-CCACATACCGTTTTCTTGTTTCCAGCC-3′ [12].
y centrifugation at 2000× g for 3min. The pellets were washed
nce with PBS, resuspended in the opsono buffer [26], and aliquots
ontaining 2.5×106 CFU were incubated with heat-inactivated
nti-PspA 94/01 or 245/00 pooled sera at a ﬁnal dilution of 1:8
nd 1:16 at 37 ◦C for 30min. Sera from mice immunized with Alum
ere used as control. After another wash with PBS, the samples
ere incubated with 10% normal mouse sera (NMS) diluted in
psono buffer at 37 ◦C for 30min. The samples were then washed
nce with PBS and incubated with 4×105 peritoneal cells (see Sec-
ion 2.8) diluted in opsono buffer, at 37 ◦C for 30min with shaking
220 rpm). The reactionwas stopped by incubation on ice for 1min.
en folddilutions of the sampleswereperformedand10l aliquots
f each dilution were plated on blood agar plates. The plates were
ncubated at a 37 ◦C, 5% CO2 and the pneumococcal CFU recov-
red counted after 18h. The slides were prepared by cytospin and
tained with Instant-Prov (Newprov, Brazil). Statistical analysis of
he ﬁnal pneumococcal counts in each group was performed by
ne-way ANOVA with a Tukey’s Multiple Comparison Test.
.8. Peritoneal cells
BALB/c mice were injected i.p. with 10g of Concanavalin A
rom Canavalia ensiformis (ConA, Sigma), sacriﬁced 48h after treat-
ent and their peritoneal cavitieswashedwith5ml of ice-cold PBS.
he peritoneal cells were adjusted to 4×106/ml in opsono buffer
27].
. Results
.1. PspA expression and puriﬁcationThe N-terminal regions of 10 family 1 PspAs (5 clade 1 and
clade 2) from Brazilian pneumococcal strains (Table 1) were
xpressed in fusion with a His-tag in competent E. coli strains and
uriﬁed through Ni2+ afﬁnity chromatography. The SDS-PAGE ofFig. 1. SDS PAGE of the puriﬁed recombinant PspAs (5g). The N-terminal region of
ten family 1 PspAswas expressed in E. coli strains in fusionwithHis-tag and puriﬁed
byNi2+ afﬁnity chromatography.Molecularmassmarkers (kDa) are indicated on the
left.
the puriﬁed recombinant proteins shows that the molecular mass
varied from ∼45 to 70kDa (Fig. 1). All fragments included portions
of the proline-rich region, and PspAs 245/00, P1031, 325/95, P339
and 94/01 also comprised the non-proline block.
3.2. Cross-reactivity
Polyclonal sera from BALB/c mice immunized with two or three
doses of recombinant PspAs were examined by ELISA and showed
similar antibody titers (data not show). The pooled anti-PspA antis-
erawere tested for their ability to recognize several choline extracts
from pneumococcal strains bearing PspAs of clades 1 (six strains)
and2 (seven strains) by immunoblot. The results are shown inFig. 2.
The analysis of serum cross-reactivity among PspAs from clades 1
and 2 revealed a signiﬁcant variation in the level of recognition of
different isolates. Of all antisera tested, four presented high lev-
els of cross-reactivity with PspAs of both clades, being two from
clade 1 – PspA M12 and 245/00 – and two from clade 2 – PspA
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neumococci (5 of each clade) were tested for their ability to recognize diverse cho
arkers (kDa) are indicated on the left. The positive controls are underlined on the
4/01 and P339. These sera were selected and tested for their abil-
ty to increase complement deposition on the surface of a panel of
neumococcal stains.
.3. Complement deposition in the presence of anti-PspA
ntibodies
We also determined the ability of the four selected anti-PspA
era to increase complement deposition on the surface of vari-
us pneumococci. Eight pneumococcal strains expressing family 1
spAs were incubated with the heat-inactivated pooled sera from:
spA 245/00, PspA M12, PspA 94/01, PspA P339, PspA P 278 or
erum from mice injected with only Al(OH)3 followed by the addi-
ion of 10% fresh-frozen normal mouse serum. The samples were
ashed and labeled with FITC-conjugated goat anti-mouse C3. The
ercentage of bacteria coated with C3 >10 ﬂuorescence intensity
nits was determined by ﬂow cytometry.
Antibodies generated against PspA 245/00, when incubated
ith pneumococcal strains expressing clade 1 PspAs, efﬁciently
ncreased C3 deposition, in all serotypes tested. Interestingly, the
ame was observed with strains bearing clade 2 PspAs, even
train A66.1, which is a heavily encapsulated serotype 3 strain
Figs. 3 and 4). Fig. 4 summarizes the complement deposition
esults, after discounting the non-speciﬁc interaction, revealing a
ercentage of ﬂuorescent bacteria not lower than 30% for all strains
ested. On the other hand, antibodies generated against PspA M12
nduced lower C3 deposition in both PspA clade 1 and clade 2 con-
aining strains (Figs. 3 and 4). As for antibodies produced againstl sera from mice immunized with the N-terminal regions of PspAs from 10 family 1
tracts (2g) of pneumococcal strains bearing PspAs clade 1 and 2. Molecular mass
ght of each blotting. The four most cross-reactive anti-sera are highlighted.
PspAclade2, anti-PspA94/01enhanced theamountofC3deposited
on all bacteria tested, regardless of the PspA clade expressed on
their surface. Anti-PspA P339, on the other hand, showed the poor-
est results, leading to an increase in the amount of C3 deposited on
only half of the pneumococcal strains tested. Corroborating with
the immunoblot results, a poorly cross-reactive serum in that assay,
P278, also showed a reduced ability to induce complement depo-
sition in most of the strains (Figs. 3 and 4).
In summary, antibodies generated against PspA 245/00 and
94/01 were able to increase complement deposition on the widest
range of pneumococci tested, being selected for further investi-
gation of their potential to mediate opsonophagocytic killing by
peritoneal cells.
3.4. Opsonophagocytic assay
The two most cross-reactive sera selected from complement
deposition assays, anti-PspA 245/00 and 94/01, were tested for
their ability to block PspA’s anti-phagocytic activity, therefore
promoting pneumococcal opsonization by deposition of comple-
ment and phagocytosis by peritoneal cells (macrophages and
neutrophils). The antisera were tested at two different dilutions,
1:8 and 1:16. Fig. 5 shows the number of CFUs recovered after incu-
bation of pneumococci with peritoneal cells in the presence of sera
at the dilution of 1:16with the exception for Strain P 1079 inwhich
the anti-PspA 94/01 opsonophagocitic activity was observed only
at a dilution of 1:8. The anti-PspA245/00 antisera (clade 1)was able
to reduce the number of CFUs recovered in at least 40% for strains
1638 C. Goulart et al. / Vaccine 29 (2011) 1634–1642
F face in
P with
2 mmun
g ty uni
b
r
m
a
P
w
r
s
a
w
i
b
s
e
big. 3. Comparison of complement protein C3 deposition onto pneumococcal sur
125, 245/00 and P630), and clade 2 (A66.1, D39, 94/01 and P854) were incubated
45/00, Anti-PspA P 339, Anti-PspA 94/01 and Anti-PspA P 278). Serum from mice i
ray-shaded areas. The percentage of ﬂuorescent bacteria (>10 ﬂuorescence intensi
earing PspA clade 1 and 30% for strains containing clade 2 PspA,
eaching a maximum of 50% in strains of the same clade. Further-
ore, sera from mice immunized with PspA 94/01 (clade 2), was
ble to mediate killing of at least 30% of the bacteria expressing
spAs clade 1 or 2. The only exception was that of strain P278, for
hich the reduction in CFU recoveredwas only 17%. Themaximum
eduction induced by anti-PspA 94/01 antisera was 46 and 63% for
trains bearing PspA 1 and 2, respectively. The CFU reductionmedi-
ted by anti-PspA 245/00 and 94/01 was statistically signiﬁcant
hen compared to serum from mice receiving Aluminum hydrox-
de (except for strain P 278). Both sera induced similar degrees of
acterial phagocytosis amongpneumococci bearing family 1PspAs,
ince therewere no statistically signiﬁcant differences between the
ffect induced by anti-PspA 245/00 and anti-PspA 94/01 antisera.
Microscopical analysis of the samples revealed the interaction
etween the phagocytes and the pneumococci incubatedwith boththe presence of the selected anti-PspA sera. Strains bearing PspAs clade 1 (P69,
sera from mice immunized with recombinant PspAs. (Anti-PspA M12, Anti-PspA
ized with Alum was used as a control for each bacterium and is represented by the
ts) was calculated for each sample.
sera (Fig. 6). In the control group, after incubation of the cells
with bacteria previously treated with non-speciﬁc antibodies, no
interaction was observed, as depicted by the mononuclear cell in
Fig. 6A. On the other hand, incubation of the cells with a PspA
clade 1 expressing strain, previously opsonized with anti-PspA
94/01 (clade 2), induced a strong interaction between the bacteria
and the peritoneal cells, as demonstrated by the pneumococci-
covered macrophage in Fig. 6 B. Noteworthy is the ability of
the anti-PspA 94/01 antibodies to mediate phagocytosis of a
pneumococcal strain expressing a heterologous PspA, a strong indi-
cation of cross-protection. A similar result was obtained when
cells were cultured in the presence of the pneumococcal strain
P 69, containing PspA clade 1, previously incubated with anti-
PspA245/00, also clade 1; Fig. 6C and D shows a large number of
internalized bacteria in a macrophage and a neutrophil, respec-
tively.
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. Discussion
PspA is a promising vaccine candidate against pneumococcal
isease; however, it is structural and serological variability could
imit the coverage of a PspA-based vaccine. Therefore, under-
tanding the nature of PspA’s variability has been the focus of
any studies regarding anti-pneumococcal vaccine development.
ollingshead et al. [12], grouped most PspAs into two major fam-
lies, 1 and 2, which were subdivided into 5 clades. PspAs of
he same family share 55–80% of the so-called clade deﬁning
egion, while sequence similarity between families is <55%. It has
een demonstrated that the level of cross-reactivity and cross-
rotection among PspAs correlates with sequence similarity, being
ow between PspAs of different families and higher within each
amily. Furthermore, it has been suggested that the level of cross-
eactivity and cross-protection varies depending on the PspA clade
21]. In that study, a PspA from clade 3 elicited antibodies with the
owest cross-reaction, while PspAs 4 and 5 (belonging to family 2)
ere highly cross-reactive. For family 1 molecules, neither PspA
lade 1 nor clade 2 were able to induce antibodies cross-reactive to
ll family 1 strains tested. Therefore, further research was needed
o better understand cross-reactivity within family 1.
In the present study, the N-terminal regions of ﬁve clade 1
nd ﬁve clade 2 PspAs were produced, antibodies generated and
creened for their cross-reactivity against a panel of Brazilian
trains containing clade 1 and 2 PspAs. The immunoblot analy-
is revealed a high heterogeneity in the level of cross-reactivity
f the different antisera; while most cross-reacted mainly within
he homologous clade, four PspAs – 245/00, M12, 94/01 and P339 –
enerated antibodies able to recognize most of the isolates tested.
here was no predominance between the PspA clade and the level
f cross-reaction; clades 1 and 2 were equally cross-reactive.
The hybridization of the reverse primers in distinct regions
ithin the proline-rich moiety generated fragments with different
izes; all fragments included the entire alfa-helical domain plus the
eginning of the proline-rich region, and some were longer, con-
aining most of the proline block, several including the nonproline
lock. Although there was no clear correlation between the size
f the fragment and the level of cross-reactivity by immunoblot
the most cross-reactive fragments included both long and shortPercentages of bacteria positive for C3 deposition after incubation with antisera are
ounted.
proteins – in the more stringent assays – complement deposition
and OPA – the two best candidates included the proline-rich region
with the nonproline block. This result suggests a possible role for
the proline-rich region with the nonproline block in the induction
of functional antibodies. This data is in agreement with a recent
study demonstrating that immunization of mice with the proline-
rich region including the nonproline block was able to protect mice
against fatal challenge [28].
Complement mediated antibody-dependent phagocytosis is
considered to be an important mechanism of pneumococcal
clearance [29]. The ability of anti-PspA antibodies to promote com-
plement deposition on the bacterial surface greatly contributes to
their protective effect [11]. It has been demonstrated, however,
that the level of complement deposited depends on the similarity
between the PspA used to induce the antibodies and that expressed
by the pneumococcus [21,30]. In order to assess this important
functional property, antibodies to the four selected PspAs were
tested for their ability to induce complement deposition on several
pneumococcal strains. Flow cytometric analysis of the interaction
of the generated antibodieswith diverse pneumococci showed that
antibodies to PspA 245/00 and 94/01were able to increase comple-
ment deposition on the widest range of pneumococci tested. The
complement deposition on the different pneumococci appeared
to be also inﬂuenced by the serotype. We observed that some
serotypes exhibited an increased complement deposition in the
absence of anti-PspA antibodies, as demonstrated previously with
serotype 6B strains [31].
We tested the ability of these antisera to induce the comple-
ment deposition in pneumococcal strains bearing family 2 PspAs
(data not shown), and no increase in complement deposition was
observed. This result is in accordance with our previous ﬁnd-
ings [21], and suggests that, although some family 1 molecules
can broaden cross-reactivity within this family, this effect is not
extended to family 2. Our results demonstrated a signiﬁcant vari-
ability in the cross-reactivity of antisera generated against PspAs
of the same clade, which correlates with differences in antibody
mediated complement deposition on pneumococci.
In order to correlate the results of cross-reactivity with pro-
tection, we evaluated the ability of the two most cross-reacting
sera to promote the opsonophagocytosis of different pneumococ-
1640 C. Goulart et al. / Vaccine 29 (2011) 1634–1642
Fig. 5. Opsonophagocytic assay: Pneumococcal strains bearing family 1 PspAs were incubated with serum from mice immunized with recombinant PspAs 245/00 or 94/01
(clade 1 and 2, respectively) and NMS (complement source). The opsonized pneumococci were incubated with peritoneal cells and plated on blood agar plates. Serum from
mice immunized with Alum was used as a control for each bacterium. The number of CFU recovered after 18h were compared by one-way ANOVA with a Tukey’s Multiple
Comparison Test. The bars represent the standard error of the mean (SEM) and the asterisks indicate statistically signiﬁcant differences (**p<0.001; *p<0.01). Results are
representative of two independent experiments.
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al strains by peritoneal phagocytes. Since it has been difﬁcult to
how killing using the classical OPA by anti-PspA antisera (unpub-
ished data), we have optimized this assay in order to overcome
he protective effect of the capsule. Using peritoneal cells recov-
red from mice stimulated with a polyclonal T-cell activator, we
ere able to demonstrate the ability of anti-PspA antibodies to
nduce complement mediated phagocytosis of pneumococci of dif-
erent serotypes. The results demonstrate that both sera were
ble to induce complement-mediated phagocytosis leading to a
inimum reduction of 30% on the number of pneumococci. This
ffect was observed for pneumococci of diverse capsular types,
ncluding serotypes 1, 3 and 6B, demonstrating the viability of this
dapted opsonophagocytic assay for measuring the protective role
f anti-PspA antibodies, which can overcome the inhibitory effects
f different capsule types. Although these two sera were gener-
ted against PspAs of different clades, both were equally efﬁcient
gainst all family 1 strains. These results are in accordance with
he complement deposition assay, in which both sera were able
o increase complement deposition onto pneumococci containing
spA clades 1 and 2. This cross-reactive effect within strains bear-
ng family 1 PspA has been previously reported using anti-PspA1
ntibodies [21,22]. Moreno et al. [22] also demonstrated that the
mmunization of mice with PspA 4 or PspA 5 was able to induce
ross-protection against intranasal challenge with a PspA clade 2
earing strain. More recently, immunization with a clade 5 PspA
sing DTP as an adjuvant was able to broaden cross-protection
gainst family 1 strains, in an intranasal challenge model [32].
Altogether, our results indicate that antibodies generated
gainst PspAs of the same clade induce different levels of cross-
eactivity. The sera induced against two PspAs 245/00 and 94/01,
lade 1 and clade 2, respectively, were able to induce greater
omplement deposition on pneumococcal strains containing PspAs
rom family 1. Furthermore, these two sera were able to induce the
psonophagocytosis of pneumococcal strains by peritoneal cells
educing CFU recovery, suggesting a potential protective effect.We
herefore suggest that the inclusion of either one of the two PspAs,
45/00 or 94/01, in a PspA-based anti-pneumococcal vaccine could
nduce broad protection against pneumococcal strains containing
amily 1 PspAs. This protein could be used in combination with a
amily 2 molecule, selected by a similar strategy, in order to extend
rotection to pneumococcal strains bearing PspAs of both families
and 2, which should provide a high coverage.
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